
Latest News
Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario
February 20, 2025
Apo-Teriparatide Injection ™ is a generic alternative to Forteo®.
Osteoporosis pharmacologic therapies are classified as antiresorptive therapy, which inhibits osteoclastic activity, and anabolic therapy, which stimulates new bone formation. Apo-Teriparatide is an anabolic therapy.
To view more information about provincial and territorial drug coverage visit https://osteoporosis.ca/provincial-territorial-drug-coverage/
OC MAKES THE NEWS – RECENT ITEMS
Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario
February 20, 2025
Latest News Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario February 20, 2025 Apo-Teriparatide Injection ™ is a generic alternative to Forteo®. Osteoporosis pharmacologic therapies are classified […]
2024 Gideon A. Rodan Excellence in Mentorship Award
August 16, 2024
Latest News 2024 Gideon A. Rodan Excellence in Mentorship Award Angela Cheung, M.D., Ph.D. is the recipient of the 2024 Gideon A. Rodan Excellence in Mentorship Award which is given […]
Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis.
May 31, 2024
Latest News Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis. May 31, 2024 Health Canada has provided authorization to market Jubbonti® (denosumab […]